- Home
- ICCM vs ANL Comparison
ICCM vs ANL Comparison
Compare ICCM & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ICCM | ANL |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | Israel | Cayman Islands |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 350.9M |
| IPO Year | 2013 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ICCM | ANL |
|---|---|---|
| Price | $0.69 | $8.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.50 | ★ $16.00 |
| AVG Volume (30 Days) | 136.9K | ★ 214.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.87 | N/A |
| Revenue Next Year | $31.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.88 |
| 52 Week High | $1.53 | $12.09 |
Technical Indicators
Market Signals| Indicator | ICCM | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 58.32 | 55.38 |
| Support Level | $0.58 | $1.37 |
| Resistance Level | $0.74 | $10.15 |
| Average True Range (ATR) | 0.04 | 0.97 |
| MACD | 0.01 | -0.27 |
| Stochastic Oscillator | 67.81 | 56.12 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.